ProCE Banner Activity

Oral Treatments for HER2-Negative Early-Stage Breast Cancer: A Guide for Patients and Caregivers

PDF

Download this resource to support patient adherence and persistence to oral anticancer therapies for HER2-negative early-stage breast cancer, including CDK4/6 inhibitors, PARP inhibitors, and endocrine therapy.

Released: June 05, 2024

Expiration: June 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Breastcancer.org

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme, LLC, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner

Disclosure

Primary Author

Julia A LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
UCLA Hematology Oncology
Santa Monica, California

Julia A. LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo.